News

The restraining order related to alleged infringement of Oxandrin patents held by Savient. Oxandrin is an oral anabolic agent indicated as adjunctive therapy to promote weight gain and

Analysis of data from the study showed that Promacta at 50mg or 75mg resulted in a positive trend in decrease in bleeding incidence in adult patients with chronic

The initial focus of the agreement will be Fentora, which received FDA approval in September 2006, for the management of breakthrough pain in patients with cancer who are

Under the terms of the agreement, Merck will receive rights to a number of Idera's agonist compounds targeting Toll-like Receptor (TLR) 7, 8 and 9 for use in

The results were from a study of high-risk MDS and AML post-MDS patients treated under the French ATU, which provides a temporary authorization for compassionate use of Vidaza

The study evaluated patients with chronic myelogenous leukemia, Philadelphia chromosome-positive acute lymphocytic leukemia and myeloproliferative disorders, or MPD, a group of blood diseases that can develop into leukemia.

The company now plans to commence its previously-announced phase IIa clinical trial for MEM 3454 in Alzheimer's disease during the first quarter of 2007. The FDA had originally

The companies also said that a phase III trial in catheter occlusion did not meet the endpoint of restoration of function at 15 minutes. These trials did not

The primary objective was to answer whether the Xelox (oral Xeloda plus oxaliplatin) regimen is as effective as Folfox-4 (infused 5-FU/leucovorin plus oxaliplatin) in delaying disease progression or